BlueLinx (BXC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
The annual meeting is scheduled for May 14, 2026, at the company’s headquarters, with voting on director elections, auditor ratification, executive compensation, and an amendment to the long-term incentive plan.
Shareholders of record as of March 20, 2026, are eligible to vote, with a majority required for approval of most proposals.
Proxy materials, including the annual report and proxy statement, are available online and by mail.
Voting matters and shareholder proposals
Shareholders will vote to elect nine directors, ratify Ernst & Young LLP as the independent auditor for fiscal 2026, approve executive compensation on an advisory basis, and approve an amendment to the 2021 Long-Term Incentive Plan to increase reserved shares by 750,000.
The board recommends voting FOR all proposals and nominees.
Majority voting standard for uncontested director elections was adopted in February 2026.
Board of directors and corporate governance
The board consists of nine members, with Christina M. Corley appointed in September 2025 to fill a vacancy.
All directors except the CEO are independent; the board is led by a non-executive chairman.
Three standing committees: Audit, Human Capital and Compensation, and Nominating and Governance, each with independent members and written charters.
Director nomination process emphasizes diversity, experience, and independence.
Director stock ownership guidelines require non-employee directors to own shares equal to five times the cash retainer.
Latest events from BlueLinx
- Q2 2026 saw 4.4% sales growth, margin expansion, and strong cash flow and liquidity.BXC
Q2 2026 - Q1 2026 net sales up 3.1% to $731M, specialty growth, strong liquidity, and higher margins.BXC
Q1 2026 - Flat sales, specialty growth, and strong liquidity amid market headwinds and margin pressure.BXC
Q4 2025 - Director elections, auditor ratification, and executive pay are key 2025 meeting agenda items.BXC
Proxy Filing - Q2 2025 sales rose 2%, but net income and margins declined amid higher costs and price deflation.BXC
Q2 2025 - Net sales fell 7.7%-8%, but strong cash flow and liquidity supported capital returns.BXC
Q3 2024 - Q2 2024 net sales fell 5.8%-6%, but specialty margins and liquidity remained strong.BXC
Q2 2024 - Q1 2025 net sales fell 2.3% as margins compressed, but liquidity and repurchases stayed strong.BXC
Q1 2025 - 2024 net sales hit $3.0B, with strong margins, liquidity, and $45M in share repurchases.BXC
Q4 2024